Original language | English |
---|---|
Pages (from-to) | 2263-2265 |
Number of pages | 3 |
Journal | JACC: Cardiovascular Interventions |
Volume | 13 |
Issue number | 19 |
DOIs | |
State | Published - 12 Oct 2020 |
Externally published | Yes |
Keywords
- PCI
- bleeding risk
- dual antiplatelet therapy
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Cardiovascular Interventions, Vol. 13, No. 19, 12.10.2020, p. 2263-2265.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - Duration of Dual Antiplatelet Therapy After PCI
T2 - How Short Can We Go?
AU - Baber, Usman
AU - Angiolillo, Dominick J.
N1 - Funding Information: Dr. Baber has received consulting honoraria from Amgen, Boston Scientific, and AstraZeneca. Dr. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; and has received payments for participation in review activities from CeloNova and St. Jude Medical; and his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation. Funding Information: Dr. Baber has received consulting honoraria from Amgen, Boston Scientific, and AstraZeneca. Dr. Angiolillo has received consulting fees or honoraria from Abbott, Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; and has received payments for participation in review activities from CeloNova and St. Jude Medical; and his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation.
PY - 2020/10/12
Y1 - 2020/10/12
KW - PCI
KW - bleeding risk
KW - dual antiplatelet therapy
UR - http://www.scopus.com/inward/record.url?scp=85091695619&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2020.07.005
DO - 10.1016/j.jcin.2020.07.005
M3 - Editorial
C2 - 32950420
AN - SCOPUS:85091695619
SN - 1936-8798
VL - 13
SP - 2263
EP - 2265
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 19
ER -